Curing all patients with acute promyelocytic leukemia: are we there yet? - Test2 - elhamkhani - TriplyDB

Curing all patients with acute promyelocytic leukemia: are we there yet?

Curing all patients with acute promyelocytic leukemia: are we there yet?

http://www.wikidata.org/entity/Q33613426

about

Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo Value of oligonucleotide-based array comparative genomic hybridization for diagnosis of acute promyelocytic leukemia in a patient negative for t(15;17)(q24.1;q21.2)/promyelocytic leukemia-retinoic acid receptor, alpha by conventional cytogenetics an The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.Arsenic trioxide stabilizes accumulations of adeno-associated virus virions at the perinuclear region, increasing transduction in vitro and in vivo.All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis.Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia.

P2860

Q28488457-558A28B6-19A3-41E5-9B35-7F5BBE10E54C Q34652091-58A9F214-56B6-464C-A84D-A7DD108CDF83 Q36508924-5DAA891F-C530-45DC-8F0B-9A897D090ED4 Q36760126-D150219E-A0CA-4D33-81D1-D30633A58350 Q37663363-609550E3-FB69-4C36-9BB9-1A436F1B7223 Q38798789-248410DE-85DB-4624-926C-D71D6BFD5D40 Q40269702-5458696E-E8F5-4036-8555-C7860BCF3FDF Q41530079-0CAE368B-A4B2-40E7-AFEC-B398848D1F65 Q43089875-4A67A721-885E-4155-83D4-EAFEFA45EF7F Q47290687-E923BBA6-8338-4797-BC2E-026490601CF0

P2860

Curing all patients with acute promyelocytic leukemia: are we there yet?

http://www.wikidata.org/entity/Q33613426

description

2011 nî lūn-bûn

@nan

2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Curing all patients with acute promyelocytic leukemia: are we there yet?

@ast

Curing all patients with acute promyelocytic leukemia: are we there yet?

@en

type

label

Curing all patients with acute promyelocytic leukemia: are we there yet?

@ast

Curing all patients with acute promyelocytic leukemia: are we there yet?

@en

prefLabel

Curing all patients with acute promyelocytic leukemia: are we there yet?

@ast

Curing all patients with acute promyelocytic leukemia: are we there yet?

@en

P1433

Q33613426-35876D47-4AAB-474C-94AE-FB68793254F5

P1476

Q33613426-B0CF7C1C-E340-4B22-8073-2A03150562B6

P2093

Q33613426-5FB26F56-637D-4D86-94DE-2F8D327FCA2F

Q33613426-631A3DE4-9DA1-477E-9FDF-8B689EA6D37E

Q33613426-88D4B2A4-7D4E-492B-A7A5-82BF30ADB14B

Q33613426-A9E456C8-96D1-4668-918C-2D7B7D18A91E

Q33613426-FD0A06CC-D703-42CF-9570-B34BB1732CE0

P2860

Q33613426-02E8CEA1-CA80-4649-B6E7-0E0AA8F802F4

Q33613426-036C8965-673C-4592-8931-B12A7A47D8C4

Q33613426-0542F322-6AE2-4F01-91B8-1024E0D5B1D8

Q33613426-0AE19378-AD6E-48C5-849A-8D8492AC1F7A

Q33613426-0BCECCE6-7254-4F08-8FC3-225F7CF612BB

Q33613426-0CDA4AED-4FD8-470F-B0FB-69A1AD8B1038

Q33613426-0EF1D488-25EB-4E1C-8C43-E868B8A59B1D

Q33613426-11676661-8998-4812-8F30-A34F10244DD0

Q33613426-15F6127D-21FC-4FA2-9509-54B903524D65

Q33613426-1E5D8013-1587-4117-9E84-2CE9CF0EC722

P304

Q33613426-48C2C52E-BFDB-4800-ACCC-883C512E5156

P31

Q33613426-A8EC2CB2-8184-419F-BA96-2CBA606E1186

P356

Q33613426-1D1E6D6A-D745-4102-A4B3-2C5ED0469E02

P433

Q33613426-71D91FF5-D0D7-4174-BB02-D35078265285

P478

Q33613426-972F3599-BCBA-44A6-9A13-BB74BF353D60

P50

Q33613426-CAC9AD0F-FDC2-486A-9D5A-7799AD65EE5B

P577

Q33613426-043CCA7F-FA8C-4CF3-BFE9-AFB16CD94A4B

P698

Q33613426-5EF37534-8A6F-4708-A9DF-256867F10B85

P921

Q33613426-CBA546B6-79D9-47ED-A9E2-64065F9D1E5A

P932

Q33613426-B719E99C-6E23-427B-8D12-56EF3610B623

P356

J.HOC.2011.10.002

P1433

Hematology / Oncology Clinics of North America

P1476

Curing all patients with acute promyelocytic leukemia: are we there yet?

@en

P2093

Dan Douer

http://www.w3.org/2001/XMLSchema#string

Eytan Stein

http://www.w3.org/2001/XMLSchema#string

Jae H Park

http://www.w3.org/2001/XMLSchema#string

Jessica K Altman

http://www.w3.org/2001/XMLSchema#string

Muhamed Baljevic

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group

Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia

Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups

Interactions of STAT5b-RARalpha, a novel acute promyelocytic leukemia fusion protein, with retinoic acid receptor and STAT3 signaling pathways

All-trans-retinoic acid in acute promyelocytic leukemia

Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group

All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results

Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution

P304

1215-33, viii

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.HOC.2011.10.002

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Martin S Tallman

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22093584

http://www.w3.org/2001/XMLSchema#string

P921

P932

4021483

http://www.w3.org/2001/XMLSchema#string